John joined Vicarious Surgical in March of 2022 as SVP of Operations and has over 35 years of medical device industry experience.
He has been involved with over 25 medical device product launches encompassing both Class II and Class III devices.
Prior to joining the Vicarious Surgical team, he spent 13 years in senior executive roles and product development leadership positions, including serving as VP of Operations at Becton Dickinson Surgery overseeing a network of 10 manufacturing sites, a business planning and procurement organization, an advanced manufacturing engineering team, and the business' environmental health and safety responsibilities.
In the past year, John has led strategic manufacturing plans for the Vicarious Surgical robotic system, overseeing operations and quality organizations.
In the newly created chief operating officer role, John's oversight expands to include the Product Development, Clinical & Regulatory Affairs, IT and People & Culture functions of the business for enhanced workflow efficiency and a continued focus on manufacturing and procurement optimization.
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs.
The company's novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery.
The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC.
The company is headquartered in Waltham, Massachusetts.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project